Ebos Group Valuation Multiples

Ebos Group Overview

About Ebos Group

Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government’s Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.

Founded

1922

HQ

Employees

5.8K

Website

ebosgroup.com

Sectors

Pharmacies

Financials (LTM)

Revenue: $9B

EBITDA: $435M

EV

$4B

Valuation Multiples

Multiples.vc

Start free trial

Ebos Group Financials

Ebos Group reported last 12-month revenue of $9B and EBITDA of $435M.

In the same LTM period, Ebos Group generated $1B in gross profit, $435M in EBITDA, and $180M in net income.

Ebos Group P&L

In the most recent fiscal year, Ebos Group reported revenue of $8B and EBITDA of $379M.

Ebos Group expects next 12-month revenue of XXX and NTM EBITDA of XXX

Ebos Group Stock Performance

Ebos Group has current market cap of $3B, and enterprise value of $4B.

Ebos Group's stock price is $13.03.

Ebos Group Valuation Multiples

Ebos Group trades at 0.4x EV/Revenue multiple, and 8.6x EV/EBITDA.

Ebos Group Financial Valuation Multiples

As of April 20, 2026, Ebos Group has market cap of $3B and EV of $4B.

Equity research analysts estimate Ebos Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Ebos Group has a P/E ratio of 14.8x.

Ebos Group Margins & Growth Rates

Ebos Group's revenue in the last 12 month grew by 8%.

Ebos Group's revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $0.1M for the same period.

Ebos Group's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Ebos Group's rule of X is 40% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Ebos Group Public Comps

See public comps and valuation multiples for other Pharmacies comps.

Ebos Group M&A Activity

Ebos Group acquired XXX companies to date.

Last acquisition by Ebos Group was on XXXXXXXX, XXXXX. Ebos Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Ebos Group Investment Activity

Ebos Group invested in XXX companies to date.

Ebos Group made its latest investment on XXXXXXXX, XXXXX. Ebos Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).